ID   CS-1/PR
AC   CVCL_F1B3
SY   CS-1/Zal
DR   GEO; GSM419914
RX   PubMed=19742314;
CC   Population: Caucasian.
CC   Characteristics: Exhibits cross resistance to cisplatin and methotrexate but not to doxorubicin (PubMed=19742314).
CC   Selected for resistance to: ChEBI; CHEBI_235523; Zalypsis (PM00104).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Bone, humerus; UBERON=UBERON_0000976.
DI   NCIt; C2946; Chondrosarcoma
DI   ORDO; Orphanet_55880; Chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_T023 ! CS-1 [Human chondrosarcoma]
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 27-11-25; Last updated: 27-11-25; Version: 1
//
RX   PubMed=19742314; DOI=10.1371/journal.pone.0006967; PMCID=PMC2734182;
RA   Duan, Zhen-Feng
RA   Choy, Edwin
RA   Harmon, David C.
RA   Yang, Cao
RA   Ryu, Keinosuke
RA   Schwab, Joseph H.
RA   Mankin, Henry J.
RA   Hornicek, Francis John
RT   "ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and
RT   PM00104 (Zalypsis) in human cancer cell lines.";
RL   PLoS ONE 4:e6967.1-e6967.10(2009).
//